Along with the development of different tracers that can target beta-amyloid (9), tau protein (10), synaptic vesicle glycoprotein 2A (SV2A) density (11), acetylcholine (12), brain perfusion (13), and dopaminergic system (14), the role of radionuclide imaging, including PET and SPECT, in neurodegenerative diseases is well recognized. This evidence concerns the gene SV2A and neurodegenerative disease.